Keros Therapeutics (NASDAQ:KROS) Stock Rating Reaffirmed by Piper Sandler
Keros Therapeutics (NASDAQ:KROS – Get Free Report)‘s stock had its “overweight” rating reissued by equities research analysts at Piper Sandler in a research report issued on Wednesday, Benzinga reports. They currently have a $105.00 price objective on the stock. Piper Sandler’s target price suggests a potential upside of 58.61% from the stock’s previous close. A […]
More Stories
Beyond Hormuz: The US–Indonesia Defense Pact and What It Means for China
By Antonio Graceffo The U.S.–Indonesia defense pact strengthens American strategic control over key maritime chokepoints, enhancing its ability to pressure...
Iran Signals It May Skip Next US-Led Peace Talks as Israel Warns of Renewed Fighting
By Tom Ozimek Iran signaled fresh uncertainty around U.S.-backed peace efforts on April 20, saying it has yet to decide...
Is Love Story Season 2 Renewed? Release Date, Cast, and Spoiler
Ryan Murphy’s latest series, Love Story Season 1, has raised the bar with the 90’s romance featuring Sarah Pidgeon and...
Fifty Shades of Grey Star, Dakota Johnson, Net Worth and Salary in 2026
The Fifty Shades of Grey lead actress is once again in the spotlight after she appeared kissing her recent boyfriend,...
CapCut Vs InShot: Which is the Best Video Editing Tool?
Videos have become one of the most useful and important tools for every marketing organization. In this digital era, more...
Louisiana Gunman Kills at Least 8 Children in Morning Shooting Spree
By Jacki Thrapp At least eight children were killed during a shooting in Shreveport, Louisiana, on the morning of April...